Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Butler PC, Elashoff M, Elashoff R et al
Lenmeldy is the first FDA-approved gene therapy for MLD, which is caused by a deficiency of the arylsulfatase A (ARSA) enzyme, a state that leads to a buildup of fatty substances in the cells
We recommend sloshing around all parts of the mouth
Boehringer Ingelheim International GmbH Scope of Report GLP-1 Receptor Agonist Market Analysis by Segments Drug: Semaglutide Exenatide Lixisenatide Liraglutide Dulaglutide Others Route of Administration: Oral Parenteral Indication: Diabetes Obesity Others Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Region: North America Latin America Europe Asia-Pacific Middle East & Africa Bibliography Pharmaceutical Executive
US$ 25.66
US$ 26.02
US$ 25.68
US$ 27.06
US$ 28.35
US$ 20.81
US$ 25.24
